Establishment Labs to Announce Fourth Quarter 2024 Financial Results on February 26
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company focused on women's health and breast aesthetics, will release its Q4 2024 financial results after market close on February 26, 2025. The company will host a conference call at 4:30 pm ET to discuss the results.
The company has delivered over four million Motiva® devices to surgeons since 2010 across 90+ countries. Their product portfolio includes Mia Femtech®, Preservé™ for breast augmentation, GEM® for gluteal modeling, Motiva Flora® tissue expander, and Zensor™ RFID technology platform. The company operates two FDA-compliant manufacturing facilities in Costa Rica and holds over 200 patent applications across 20 families, supported by 100+ scientific studies.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), un'azienda globale di tecnologia medica focalizzata sulla salute delle donne e sull'estetica mammaria, pubblicherà i suoi risultati finanziari del quarto trimestre 2024 dopo la chiusura del mercato il 26 febbraio 2025. L'azienda ospiterà una conferenza telefonica alle 16:30 ET per discutere i risultati.
L'azienda ha consegnato oltre quattro milioni di dispositivi Motiva® a chirurghi in oltre 90 paesi dal 2010. Il loro portafoglio prodotti include Mia Femtech®, Preservé™ per l'aumento del seno, GEM® per la modellazione gluteale, Motiva Flora® espansore tissutale e la piattaforma tecnologica Zensor™ RFID. L'azienda gestisce due stabilimenti di produzione conformi alla FDA in Costa Rica e detiene oltre 200 domande di brevetto in 20 famiglie, supportate da oltre 100 studi scientifici.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), una empresa global de tecnología médica centrada en la salud de la mujer y la estética mamaria, publicará sus resultados financieros del cuarto trimestre de 2024 después del cierre del mercado el 26 de febrero de 2025. La empresa llevará a cabo una conferencia telefónica a las 4:30 p.m. ET para discutir los resultados.
La empresa ha entregado más de cuatro millones de dispositivos Motiva® a cirujanos en más de 90 países desde 2010. Su cartera de productos incluye Mia Femtech®, Preservé™ para aumento de senos, GEM® para modelado glúteo, Motiva Flora® expansor de tejido y la plataforma de tecnología Zensor™ RFID. La empresa opera dos instalaciones de fabricación conformes a la FDA en Costa Rica y tiene más de 200 solicitudes de patentes en 20 familias, respaldadas por más de 100 estudios científicos.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), 여성 건강과 유방 미용에 중점을 둔 글로벌 의료 기술 회사는 2025년 2월 26일 시장 마감 후 2024년 4분기 재무 결과를 발표할 예정이다. 회사는 결과를 논의하기 위해 동부 표준시 기준 오후 4시 30분에 컨퍼런스 콜을 개최할 것이다.
이 회사는 2010년 이후 90개국 이상에서 외과의사에게 400만 개 이상의 Motiva® 장치를 공급했다. 그들의 제품 포트폴리오에는 Mia Femtech®, 유방 확대를 위한 Preservé™, 둔부 모델링을 위한 GEM®, Motiva Flora® 조직 확장기 및 Zensor™ RFID 기술 플랫폼이 포함된다. 이 회사는 코스타리카에 FDA 준수 제조 시설 두 곳을 운영하며, 20개 가족에 걸쳐 200건 이상의 특허 출원을 보유하고 있으며, 100건 이상의 과학적 연구에 의해 지원받고 있다.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), une entreprise mondiale de technologie médicale axée sur la santé des femmes et l'esthétique mammaire, publiera ses résultats financiers du quatrième trimestre 2024 après la fermeture des marchés le 26 février 2025. L'entreprise organisera une conférence téléphonique à 16h30 ET pour discuter des résultats.
L'entreprise a livré plus de quatre millions de dispositifs Motiva® à des chirurgiens depuis 2010 dans plus de 90 pays. Son portefeuille de produits comprend Mia Femtech®, Preservé™ pour l'augmentation mammaire, GEM® pour le modelage des fessiers, Motiva Flora® expanseur tissulaire et la plateforme technologique Zensor™ RFID. L'entreprise exploite deux installations de fabrication conformes à la FDA au Costa Rica et détient plus de 200 demandes de brevet dans 20 familles, soutenues par plus de 100 études scientifiques.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), ein globales Medizintechnikunternehmen, das sich auf die Gesundheit von Frauen und die Brustästhetik konzentriert, wird am 26. Februar 2025 nach Börsenschluss seine Finanzzahlen für das vierte Quartal 2024 veröffentlichen. Das Unternehmen wird um 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen.
Das Unternehmen hat seit 2010 über vier Millionen Motiva®-Geräte an Chirurgen in mehr als 90 Ländern geliefert. Ihr Produktportfolio umfasst Mia Femtech®, Preservé™ zur Brustvergrößerung, GEM® zur Gesäßmodellierung, Motiva Flora® Gewebeexpander und die Zensor™ RFID-Technologieplattform. Das Unternehmen betreibt zwei FDA-konforme Fertigungsstätten in Costa Rica und hält über 200 Patentanmeldungen in 20 Familien, unterstützt von mehr als 100 wissenschaftlichen Studien.
- Strong global presence with products in over 90 countries
- Significant market penetration with 4+ million Motiva devices delivered since 2010
- Robust intellectual property portfolio with 200+ patent applications
- Extensive scientific validation with 100+ peer-reviewed studies
- None.
To participate in the conference call, dial (877) 407-8037 (
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva® devices delivered to plastic and reconstructive surgeons since 2010, the Company’s products have created a new standard for safety and patient satisfaction. The company’s minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company’s first biosensor Zenº™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patents applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250214386020/en/
Investor/Media Contact:
Raj Denhoy
415 828-1044
rdenhoy@establishmentlabs.com
Source: Establishment Labs Holdings Inc.
FAQ
When will Establishment Labs (ESTA) release Q4 2024 earnings?
How many Motiva devices has ESTA delivered since 2010?
In how many countries are ESTA products available?
How many patents does Establishment Labs (ESTA) have?
Where does ESTA manufacture its products?
